- Home
- VKTX vs BBIO Comparison
VKTX vs BBIO Comparison
Compare VKTX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- BBIO
- Stock Information
- Founded
- VKTX 2012
- BBIO 2015
- Country
- VKTX United States
- BBIO United States
- Employees
- VKTX N/A
- BBIO N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- BBIO Health Care
- Exchange
- VKTX Nasdaq
- BBIO Nasdaq
- Market Cap
- VKTX 4.6B
- BBIO 5.1B
- IPO Year
- VKTX 2015
- BBIO 2019
- Fundamental
- Price
- VKTX $42.25
- BBIO $26.49
- Analyst Decision
- VKTX Strong Buy
- BBIO Strong Buy
- Analyst Count
- VKTX 12
- BBIO 13
- Target Price
- VKTX $106.75
- BBIO $47.92
- AVG Volume (30 Days)
- VKTX 3.7M
- BBIO 2.5M
- Earning Date
- VKTX 02-05-2025
- BBIO 11-12-2024
- Dividend Yield
- VKTX N/A
- BBIO N/A
- EPS Growth
- VKTX N/A
- BBIO N/A
- EPS
- VKTX N/A
- BBIO N/A
- Revenue
- VKTX N/A
- BBIO $217,765,000.00
- Revenue This Year
- VKTX N/A
- BBIO $2,648.47
- Revenue Next Year
- VKTX N/A
- BBIO N/A
- P/E Ratio
- VKTX N/A
- BBIO N/A
- Revenue Growth
- VKTX N/A
- BBIO 2209.77
- 52 Week Low
- VKTX $17.23
- BBIO $21.62
- 52 Week High
- VKTX $99.41
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- VKTX 33.93
- BBIO 49.05
- Support Level
- VKTX $37.80
- BBIO $25.34
- Resistance Level
- VKTX $48.55
- BBIO $28.15
- Average True Range (ATR)
- VKTX 2.54
- BBIO 1.33
- MACD
- VKTX -0.45
- BBIO -0.24
- Stochastic Oscillator
- VKTX 30.11
- BBIO 24.73
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.